Mechanisms of T-cell inhibition: implications for cancer immunotherapy (Q37658886)

21 August 2017

1 reference

title

Mechanisms of T-cell inhibition: implications for cancer immunotherapy (English)

1 reference

21 August 2017

1 reference

Elizabeth A Mittendorf

series ordinal

1

1 reference

21 August 2017

Padmanee Sharma

series ordinal

2

1 reference

21 August 2017

publication date

1 January 2010

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

89-105

1 reference

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

The tumor microenvironment and its role in promoting tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

HLA class I antigen loss, tumor immune escape and immune selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Creating immune privilege: active local suppression that benefits friends, but protects foes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

T cell co-stimulation and in vivo tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Differential T cell costimulatory requirements in CD28-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

B70 antigen is a second ligand for CTLA-4 and CD28

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

A molecular perspective of CTLA-4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Src kinases Fyn and Lck facilitate the accumulation of phosphorylated CTLA-4 and its association with PI-3 kinase in intracellular compartments of T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Molecular basis of T cell inactivation by CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Costimulatory and coinhibitory receptors in anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

FOXP3 controls regulatory T cell function through cooperation with NFAT

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Peripherally induced Treg: mode, stability, and role in specific tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Human CD4+ regulatory T cells and activation-induced tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Oral tolerance and TGF-beta-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

In vivo instruction of suppressor commitment in naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Regulatory T-cell compartmentalization and trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Reversal of tumor-mediated immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Tumor-induced immune dysfunctions caused by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Myeloid-derived suppressor cells: linking inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

CTLA-4 engagement regulates NF-kappaB activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.144

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1586/ERV.09.144

1 reference

21 August 2017

1 reference